AKBA Q4 2019 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$366M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$70M+16.2% YoY

Gross Profit

$60M85.6% margin

Operating Income

-$95M-136.4% margin

Net Income

-$94M-135.8% margin

EPS (Diluted)

$-0.79

QoQ Revenue Growth

-24.4%

Cash Flow

Operating Cash Flow

-$92M

Free Cash Flow

-$92M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$771M

Total Liabilities

$376M

Stockholders' Equity

$395M

Cash & Equivalents

$148M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$70M	$60M	+16.2%
Gross Profit	$60M	$52M	+14.1%
Operating Income	-$95M	-$90M	-5.3%
Net Income	-$94M	-$88M	-6.9%

Revenue Segments

License Collaboration And Other Revenue

$41M58%

Product

$29M42%